| Magnetic nanoparticles for cancer theranostics: Advances and prospects X Li, W Li, M Wang, Z Liao Journal of Controlled Release 335, 437-448, 2021 | 131 | 2021 |
| Gut microbiota and diabetic kidney diseases: Pathogenesis and therapeutic perspectives JR Lin, ZT Wang, JJ Sun, YY Yang, XX Li, XR Wang, Y Shi, YY Zhu, ... World journal of diabetes 13 (4), 308, 2022 | 25 | 2022 |
| mRNA vaccine in cancer therapy: Current advance and future outlook Y Li, M Wang, X Peng, Y Yang, Q Chen, J Liu, Q She, J Tan, C Lou, Z Liao, ... Clinical and Translational Medicine 13 (8), e1384, 2023 | 22 | 2023 |
| Endogenous stimuli-responsive nanoparticles for cancer therapy: from bench to bedside F Xie, M Wang, Q Chen, T Chi, S Zhu, P Wei, Y Yang, L Zhang, X Li, ... Pharmacological Research 186, 106522, 2022 | 21 | 2022 |
| Single-cell transcriptomic architecture unraveling the complexity of tumor heterogeneity in distal cholangiocarcinoma H Li, L Qu, Y Yang, H Zhang, X Li, X Zhang Cellular and Molecular Gastroenterology and Hepatology 13 (5), 1592-1609. e9, 2022 | 19 | 2022 |
| HTCA: a database with an in-depth characterization of the single-cell human transcriptome L Pan, S Shan, R Tremmel, W Li, Z Liao, H Shi, Q Chen, X Zhang, X Li Nucleic Acids Research 51 (D1), D1019-D1028, 2023 | 18 | 2023 |
| A Guillain-Barre syndrome-associated SIGLEC10 rare variant impairs its recognition of gangliosides AAD Sheikh, S Gomaa, X Li, M Routledge, K Saigoh, N Numoto, T Angata, ... Journal of Autoimmunity 116, 102571, 2021 | 12 | 2021 |
| Immunotherapy in gastrointestinal cancers: advances, challenges, and countermeasures ZX Wang, YQ Pan, X Li, T Tsubata, RH Xu Science bulletin 68 (8), 763-766, 2023 | 8 | 2023 |
| Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L) 1 therapy for advanced cancers SF Mo, ZZ Cai, WH Kuai, X Li, YT Chen Frontiers in Cell and Developmental Biology 11, 1209243, 2023 | 7 | 2023 |
| Management of the COVID-19 pandemic in Singapore from 2020 to 2021: a revisit Z Liao, D Menon, L Zhang, YJ Lim, W Li, X Li, Y Zhao Reports 5 (3), 35, 2022 | 6 | 2022 |
| Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET DC Kanellis, A Zisi, Z Skrott, B Lemmens, JA Espinoza, M Kosar, ... Cell Death & Differentiation 30 (7), 1666-1678, 2023 | 5 | 2023 |
| Single Cell Atlas: a single-cell multi-omics human cell encyclopedia L Pan, P Parini, R Tremmel, J Loscalzo, VM Lauschke, BA Maron, P Paci, ... Genome Biology 25 (1), 104, 2024 | 3 | 2024 |
| Harnessing the potential of spatial multiomics: a timely opportunity X Li Signal Transduction and Targeted Therapy 8 (1), 234, 2023 | 3 | 2023 |
| The Drug Repurposing Encyclopedia (DRE): A web server for systematic drug repurposing across 20 organisms X Li, L Pan, L Sanchez-Burgos, D Hühn, O Fernandez-Capetillo BioRxiv, 2023.03. 10.532084, 2023 | 3 | 2023 |
| New regulators of the tetracycline‐inducible gene expression system identified by chemical and genetic screens V Colicchia, M Häggblad, O Sirozh, B Porebski, M Balan, X Li, ... FEBS Open bio 12 (10), 1896-1908, 2022 | 2 | 2022 |
| 粪菌移植在炎症性肠病治疗中的研究进展 李薛鑫， 胡旭明， 张德巍 胃肠病学和肝病学杂志 27 (2), 220-223, 2018 | 2 | 2018 |
| Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy X Peng, J Fang, C Lou, L Yang, S Shan, Z Wang, Y Chen, H Li, X Li Acta Pharmaceutica Sinica B, 2024 | 1 | 2024 |
| The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ X Li, I Hernandez, S Koyuncu, B Kis, M Häggblad, L Lidemalm, AA Abbas, ... EBioMedicine 103, 2024 | 1 | 2024 |
| Modulator of TMB-associated immune infiltration (MOTIF) predicts immunotherapy response and guides combination therapy ZY Qian, YQ Pan, XX Li, YX Chen, HX Wu, ZX Liu, M Kosar, J Bartek, ... Science Bulletin 69 (6), 803-822, 2024 | 1 | 2024 |
| Ursa: A comprehensive multiomics toolbox for high-throughput single-cell analysis L Pan, T Mou, Y Huang, W Hong, M Yu, X Li Molecular Biology and Evolution 40 (12), msad267, 2023 | 1 | 2023 |